α-hydroxytamoxifen, a genotoxic metabolite of tamoxifen in the rat: Identification and quantification in vivo and in vitro

Carcinogenesis

Volumn 20, Issue 1, 1999, Pages 153-160

  Boocock, David J ^a   Maggs, James L ^a   White, Ian N H ^b   Park, B Kevin ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b MRC TOXICOLOGY UNIT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA HYDROXYTAMOXIFEN; DRUG METABOLITE; GLUCURONIDE; TAMOXIFEN; UNCLASSIFIED DRUG; UNSPECIFIC MONOOXYGENASE;

ANIMAL CELL; ARTICLE; BILE DUCT; CANNULATION; CONTROLLED STUDY; DRUG BILE LEVEL; GENOTOXICITY; GLUCURONIDATION; HUMAN; HUMAN CELL; ISOTOPE LABELING; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT;

ADULT; ANIMALS; ARYL HYDROCARBON HYDROXYLASES; BILE; BIOTRANSFORMATION; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GLUCURONATES; HUMANS; HYDROXYLATION; METABOLIC DETOXICATION, DRUG; MICE; MICROSOMES, LIVER; MIDDLE AGED; MOLECULAR STRUCTURE; MUTAGENS; OXIDOREDUCTASES, N-DEMETHYLATING; RATS; RATS, SPRAGUE-DAWLEY; SULFONES; TAMOXIFEN;

EID: 0032945356     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/20.1.153     Document Type: Article

References (51)

1. Powles, T.J. (1997) Efficacy of tamoxifen as treatment of breast cancer. Semin. Oncol., 24 (suppl., 1), 1-48.
2. Powles, T., Eeles, R., Ashley, S., Easton, D., Chang, J., Dowsett, M., Tidy, A., Viggers, J. and Davey, J. (1998) Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet, 352, 98-101.
3. Fisher, B., Costantino, J.P., Redmond, C.K., Fisher, E.R., Wickerham, D.L., Cronin, W.M. and NSABP Contributors (1994) Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J. Natl Cancer Inst., 86, 527-537.
4. Smith, L.L. and White, I.N. (1998) Antiestrogen therapy: uncertainties and risk assessment. Oncology, 12 (suppl. 5), 14-22.
5. Newbold, R.R., Jefferson, W.N., Padilla-Burgos, E. and Bullock, B.C. (1997) Uterine carcinoma in mice treated nconatally with tamoxifen. Carcinogenesis, 18, 2293-2298.
6. Wogan, G.N. (1997) Review of the toxicology of tamoxifen. Semin. Oncol., 24 (suppl. 1), S1-S87.
7. Carthew, P., Martin, E.A., White, I.N.H., De Matteis, F., Edwards, R.E., Dorman, B.M., Heydon, R.T. and Smith, L.L. (1995) Tamoxifen induces short-term cumulative DNA damage and liver tumors in rats: promotion by phenobarbital. Cancer Res., 55, 544-547.
8. Williams, G.M., Iatropoulos, M.J., Djordjevic, M.V. and Kaltenberg, O.P. (1993) The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis, 14, 315-317.
9. Tannenbaum, S.R. (1997) Comparative metabolism of tamoxifen and DNA adduct formation and in vitro studies on genotoxicity. Semin. Oncol., 24 (suppl. 1), 81-86.
10. White, I.N.H., De Matteis, F., Davies, A., Smith, L.L., Crofton-Sleigh, C., Venitt, S., Hewer, A. and Phillips, D.H. (1992) Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats. DBA/2 and C57B1/6mice and in human MCL-5 cells. Carcinogenesis, 13, 2197-2203.
11. 32P-postlabelling in three rat strains exposed to dietary tamoxifen: the relationship between cell proliferation and tumour formation. Carcinogenesis, 16, 1299-1304.
12. Phillips, D.H., Carmichael, P.L., Hewer, A., Cole, K.J., Hardcastle, I.R., Poon, G.K., Keogh, A. and Strain, A.J. (1996) Activation of tamoxifen and its metabolite α-hydroxytamoxifen to DNA-binding products: comparison between human, rat and mouse hepatocytes. Carcinogenesis, 17, 89-94.
13. Martin, E.A., Carthew, P., White, I.N.H., Heydon, R.T., Gaskell, M., Mauthe, R.J., Turteltaub, K.W. and Smith, L.L. (1998) Investigation of the formation and accumulation of liver DNA adducts in mice chronically exposed to tamoxifen. Carcinogenesis, 18, 2209-2215.
14. 2-deoxyguanosinyl)tamoxifen. Biochemistry, 36, 13010-13017.
15. Pathak, D.N. and Bodell, W.J. (1994) DNA adduct formation by tamoxifen with rat and human liver microsomal activation systems. Carcinogenesis, 15, 529-532.
16. Moorthy, B., Sriram, P., Pathak, D.N., Bodell, W.J. and Randerath, K. (1996) Tamoxifen metabolic activation: comparison of DNA adducts formed by microsomal and chemical activation of tamoxifen and 4-hydroxytamoxifen with DNA adducts formed in vivo. Cancer Res., 56, 53-57.
17. Phillips, D.H., Carmichael, P.L., Cole, K.J. and Hewer, A. (1995) Modulation of DNA binding of tamoxifen and its metabolites in rat hepatocytes. Proc. Am. Assoc. Cancer Res., 36, 147.
18. Mani, C. and Kupfer, D. (1991) Cytochrome P450 mediated activation and irreversible binding of the antiestrogen tamoxifen to protein in rat and human liver. Cancer Res., 51, 6052-6058.
19. McCague, R. and Seago, A. (1986) Aspects of metabolism of tamoxifen by rat liver microsomes. Identification of a new metabolite: E-1-[4-(2-dimethylaminoethoxy)-phenyl]-1, 2-diphenyl-1-buten-3-ol N-oxide. Biochem. Pharmacol., 35, 827-834.
20. Lim, C.K., Yuan, Z.-X., Lamb, J.H., White, I.N.H., De Matteis, F. and Smith, L.L. (1994) A comparative study of tamoxifen metabolism in female rat, mouse and human liver microsomes. Carcinogenesis, 15, 589-593.
21. 5-ethyl]tamoxifen. Carcinogenesis, 16, 683-688.
22. Poon, G.K., Walter, B., Lønning, P.E., Horton, M.N. and McCague, R. (1995) Identification of tamoxifen metabolites in human Hep G2 cell line, human liver homogenate and in patients on long-term therapy for breast cancer. Drug Metab. Dispos., 23, 377-382.
23. Crewe, H.K., Ellis, S.W., Lennard, M.S. and Tucker, G.T. (1997) Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem. Pharmacol., 53, 171-178.
24. McCague, R., Parr, I.B., Leclercq, G., Leung, O.-T. and Jarman, M. (1990) Metabolism of tamoxifen by isolated rat hepatocytes: identification of the glucuronide of 4-hydroxytamoxifen. Biochem. Pharmacol., 39, 1459-1465.
25. Fromson, J.M., Pearson, S. and Bramah, S. (1973) The metabolism of tamoxifen (ICI 46474). Part I: in laboratory animals. Xenobiotica, 3, 693-709.
26. Fromson, J.M., Pearson, S. and Bramah, S. (1973) The metabolism of tamoxifen (ICI 46474). Part II: in female patients. Xenobiotica, 3, 711-714.
27. Lien, E.A., Solheim, E., Kvinnsland, S. and Ueland, P.M. (1988) Identification of 4-hydroxy-N-desmethyltamoxifen as a metabolite of tamoxifen in human bile. Cancer Res., 48, 2304-2308.
28. Poon, G.K., Chui, Y.C., McCague, R., Lonning, P.E., Feng, R., Rowlands, M.G. and Jarman, M. (1993) Analysis of phase I and phase II metabolites of tamoxifen in breast cancer patients. Drug Metab. Dispos., 21, 1119-1124.
29. Ducharme, J., Fried, K., Shenouda, G., Leyland-Jones, B. and Wainer, I.W. (1997) Tamoxifen metabolic patterns within a glioma patient population treated with high-dose tamoxifen. Br. J. Clin. Pharmacol., 43, 189-193.
30. 32P-postlabelling and use of metabolic inhibitors for two distinct pathways leading to mouse hepatic DNA adduct formation and identification of 4-hydroxytamoxifen as a proximate metabolite. Carcinogenesis, 15, 2087-2094.
31. Dasaradhi, L. and Shibutani, S. (1997) Identification of tamoxifen-DNA adducts formed by α-sulfate tamoxifen and α-acetoxytamoxifen. Chem. Res. Toxicol., 10, 189-196.
32. Shibutani, S., Dasaradhi, L., Terashima, I., Banoglu, E. and Duffel, M.W. (1998) α-Hydroxytamoxifen is a substrate of hydroxysteroid (alcohol) sulfotransferase, resulting in tamoxifen DNA adducts. Cancer Res., 58, 647-653.
33. Marques, M.M. and Beland, F.A. (1997) Identification of tamoxifen-DNA adducts formed by 4-hydroxytamoxifen quinone methide. Carcinogenesis, 18, 1949-1954.
34. 32P-postlabelled DNA adducts by the development of a novel automated on-line solid-phase extraction HPLC method. Carcinogenesis, 19, 1061-1069.
35. 14C]radiolabelled tamoxifen or toremifene to rat DNA using accelerator mass spectrometry. Chem. Biol. Interact., 106, 149-160.
36. Brown, K., Brown, J.E., Martin, E.A., Smith, L.L. and White, I.N.H. (1998) Determination of DNA damage in F344 rats induced by geometric isomers of tamoxifen and analogues. Chem. Res. Toxicol., 11, 527-534.
37. 32P-postlabelled DNA adducts in liver obtained from women treated with tamoxifen. Carcinogenesis, 16, 1651-1654.
38. Lowry, O.H., Rosebrough, N.J., Farr, A.L. and Randall, R.J. (1951) Protein measurement with the Folin phenol reagent. J. Biol. Chem., 193, 265-275.
39. Newton, D.J., Wang, R.W. and Lu, A.Y.H. (1995) Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab. Dispos., 23, 154-158.
40. Madden, S., Maggs, J.L. and Park, B.K. (1996) Bioactivation of carbamazepine in the rat in vivo: evidence for the formation of a reactive arene oxide(s). Drug Metab. Dispos., 24, 469-479.
41. Pathak, D.N., Pongracz, K. and Bodell, W.J. (1995) Microsomal and peroxidase activation of 4-hydroxytamoxifen to form DNA adducts: Comparison with DNA adducts formed in Sprague-Dawley rats treated with tamoxifen. Carcinogenesis, 16, 11-15.
42. Phillips, D.H., Carmichael, P.L., Hewer, A., Cole, K.J. and Poon, G.K. (1994) Alpha-hydroxytamoxifen, a metabolite of tamoxifen with exceptionally high DNA-binding activity in rat hepatocytes. Cancer Res., 54, 5518-5522.
43. Potter, G.A., McCague, R. and Jarman, M. (1994) A mechanistic hypothesis for DNA adduct formation by tamoxifen following hepatic oxidative metabolism. Carcinogenesis, 15, 439-442.
44. Phillips, D.H., Hewer, A., White, I.N.H. and Farmer, P.B. (1994) Co-chromatography of a tamoxifen epoxide deoxyguanylic acid adduct with a major DNA adduct formed in the livers of tamoxifen-treated rats. Carcinogenesis, 15, 793-795.
45. Osborne, M.R., Hewer, A., Hardcastle, I.R., Carmichael, P.L. and Phillips, D.H. (1996) Identification of the major tamoxifen-deoxyguanosine adduct formed in the liver DNA of rats treated with tamoxifen. Cancer Res., 56, 66-71.
46. Maus, T.P., Pearson, R.K., Anderson, R.J., Woodson, L.C. and Reiter, C. (1982) Rat phenol sulphotransferase. Assay procedure, developmental changes and glucocorticoid regulation. Biochem. Pharmacol., 31, 849-856.
47. Ramakrishna, K.V., Fan, P.W., Boyer, C.S., Dalvie, D. and Bolton, J.L. (1997) Oxo substituents markedly alter the phase II metabolism of α-hydroxybutenylbenzenes: models probing the bioactivation mechanisms of tamoxifen. Chem. Res. Toxicol., 10, 887-894.
48. Larsson, A., Orrenius, S., Holmgren, A. and Mannervik, B. (eds) (1983) Functions of Glutathione, Biochemical, Physiological, Toxicological and Clinical Aspects. Raven Press, New York.
49. Coles, B. (1985) Effect of modifying structure on electrophilic reactions with biological macromolecules. Drug Metab. Rev., 15, 1307-1334.
50. Glatt, H., Bartsch, I., Christoph, S., et al. (1998) Sulfotransferase-mediated activation of mutagens studied using heterologous expression systems. Chem. Biol. Interact., 109, 195-219.
51. Clarke, M., Collins, R., Davies, C., Godwin, J., Gray, R. and Peto, R. (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet, 351, 1451-1467.